BOLT Bolt Biotherapeutics, Inc.
Mergers ·
Bolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028.
The company had $18.1 million in cash, cash equivalents and marketable securities on June 30, 2026. It expects to report initial clinical data from its lead antibody conjugate, BDC-4182, with its third-quarter results.
The company said its cash should fund operations into 2027, including completion of the dose escalation part of the BDC-4182 study. It expects initial clinical data in the third quarter of 2026.
Bolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change.
Bolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern.
Bolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.7 million | $7.7 million |
| Research and development | $28.5 million | $57.5 million |
| Net income (loss) | -$33.4 million | -$63.1 million |
| Cash from operations | -$39.9 million | -$61.3 million |
| Cash and equivalents | $11.7 million | $7.2 million |
| Short-term investments | $15.8 million | $40.1 million |
Our latest story on this, dated Jun 6, 2025: "Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 23, 2026: "Bolt Biotherapeutics buys Prana Therapies and raises $120 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 6, 2025: "Bolt Biotherapeutics sets 1-for-20 reverse stock split, trading adjusted June 9". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 23, 2026: "Bolt Biotherapeutics buys Prana Therapies and raises $120 million". The story links the filing or release it is based on. Read the story.
Bolt Biotherapeutics, Inc. trades under the ticker BOLT on NASDAQ.
Bolt Biotherapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Bolt Biotherapeutics, Inc. is 1641281. Its filings are on SEC EDGAR.
1,926,345 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Bolt Biotherapeutics, Inc. under United States.
Our directory classifies Bolt Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Bolt Biotherapeutics, Inc. is US0977022039.
aibio.space lists Bolt Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$7.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Bolt Biotherapeutics, Inc. reported a net loss of $33.4 million for the fiscal year ended Dec 31, 2025, and used $39.9 million of cash in operations, per its annual report to the SEC.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,5.02,5.03,7.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.03). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio